ImmunoMet Therapeutics Announces the Formation of Scientific Advisory Board
Highly-Regarded Experts Have Extensive Experience in Cancer CelI and Immune Cell Metabolism
HOUSTON and DAEJEON, South Korea, March 10, 2016 /PRNewswire/ -- ImmunoMet Therapeutics, a biotechnology company developing innovative drugs for the treatment of cancer, today announced the formation of its Scientific Advisory Board (SAB) that will provide valuable insight and strategic advice to the Company.
The SAB, comprised of renowned key opinion leaders in the areas of cancer cell and immune cell metabolism, includes: Michael Pollak, M.D., Professor, Department of Oncology and Medicine, McGill University and Jewish General Hospital, Montreal, CAN, who will serve as Chairman of the SAB; Gordon Mills, M.D., Ph.D., Department Chair, Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; Erika Pearce, Ph.D., Director, Immunology and Epigenetics, Max Planck Institute, Freiburg, Germany; Russell Jones, Ph.D., Assistant Professor, Department of Physiology, Goodman Cancer Research Center, McGill University, Montreal, CAN; Jae-Ho Cheong, M.D., Ph.D., Associate Professor, Department of Surgery, Yonsei University, Seoul, Korea; and Seok-Gu Kang, M.D., PhD., Associate Professor, Department of Neurosurgery, Yonsei University, Seoul, Korea.
Sung-wuk Kim, CEO of ImmunoMet Therapeutics, said, "We are pleased to welcome this prestigious group of worldwide experts in the areas of immune cell metabolism and immuno-oncology to our SAB. Our management team looks forward to working closely with this distinguished group, as we continue to move forward with our innovative technology platforms that are focused on providing novel therapies that will benefit cancer patients."
At the Keystone Symposia on Molecular and Cellular Biology in Banff, Canada, members of the SAB and ImmunoMet management team held its first annual SAB meeting and discussed the next steps to advance the Company's development programs. Abstracts presented by members of the SAB at Keystone Symposia included: Russell Jones PhD., LKB, Links between Inflammation and Tumor Development; Erika Pearce PhD., Metabolic Pathways in Effector and Memory T-cells; Michael Pollak M.D., Targeting Cancer Metabolism with Metformin and Other Biguanides: from Bench to Bedsides and Back.
Michael Pollak M.D., said, "At McGill University, we are moving forward with laboratory studies of the Company's lead candidate, IM156, with currently-used drugs to improve their efficacy to treat cancers. The data from these studies will be used to guide the design of the Phase 2 clinical trials, following the Phase 1 evaluation planned for later this year."
About ImmunoMet Therapeutics
ImmunoMet Therapeutics is a development-stage biotechnology company, focused on the development of innovative oncology products to improve the quality of life and make a meaningful difference in the lives of cancer patients. The Company, a spinoff of HanAll Biopharma, has the extensive research and development experience of HanAll's scientists in the areas of immune cell metabolism and immuno-oncology, which address the high unmet medical need to treat drug resistant and relapse cancers. The Company's novel technology is designed to disrupt cancer cell growth and enhance anti-cancer immunity and may be used in a broad range of difficult-to-treat cancers. The Company's lead compound, IM156, for the treatment of glioblastoma (brain cancer) is expected to enter Phase 1 clinical development in the second half of 2016. For additional information about the Company, please visit www.immunomet.com.
Contact
Sanghee Yoo: [email protected]
Joseph T. Schepers: 919-616-1923, [email protected]
SOURCE ImmunoMet Therapeutics
Share this article